DPTX3496: New Drug Candidate for Colorectal, Breast, and Lung Cancers
Dewpoint Therapeutics has nominated DPTX3496, its second drug development candidate. DPTX3496 is an oral small molecule designed to treat...
4DMT to Review 52-Week Interim Phase 2b Results
4D Molecular Therapeutics will present 52-week interim data from the Phase 2b portion of its PRISM clinical trial evaluating...
Cardiovascular Devices Market to Hit $110B by 2029
The global cardiovascular devices market, valued at US$72.83 billion in 2023, is projected to reach US$110.39 billion by 2029,...
Gamma Delta T Cell Cancer Therapy Clinical Trials Overview
The global gamma delta T cell therapy market is experiencing rapid growth, driven by over 30 therapies currently in...
Targeted Alpha Therapy Clinical Trials: An Overview
Over 20 alpha therapies are currently in clinical trials, marking a significant advancement in targeted cancer treatment. These therapies...
Transforming Clinical Trials: Gen Li’s Vision for the Future
In the dynamic world of clinical trials, Gen Li of Phesi offers a unique perspective on the industry’s challenges...
First Canadian Clinic Offers C2N’s PrecivityAD2 Blood Test for Alzheimer’s
The Toronto Memory Program (TMP) is the first clinic in Canada to offer C2N Diagnostics‘ PrecivityAD2 blood test for...
Fresenius Kabi’s Adaptive Nomogram Gets FDA 510(k) Clearance
Fresenius Kabi received FDA 510(k) clearance for its Adaptive Nomogram, an algorithm designed to optimize plasma collection efficiency for...
Cebranopadol Shows Low Abuse Potential in Clinical Trial
Tris Pharma announced positive clinical data from its intranasal human abuse potential (HAP) study of cebranopadol. The study demonstrated...
Cebranopadol Shows Low Abuse Potential in Clinical Trial
Tris Pharma announced positive results from a Phase 1 intranasal human abuse potential (HAP) study of cebranopadol. The study...